EA201792317A1 - Ингибитор бромодомена - Google Patents
Ингибитор бромодоменаInfo
- Publication number
- EA201792317A1 EA201792317A1 EA201792317A EA201792317A EA201792317A1 EA 201792317 A1 EA201792317 A1 EA 201792317A1 EA 201792317 A EA201792317 A EA 201792317A EA 201792317 A EA201792317 A EA 201792317A EA 201792317 A1 EA201792317 A1 EA 201792317A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methylisoquinolin
- methylsulfonylphenyl
- cyclopropylmethoxy
- bromodomain inhibitor
- pharmaceutical composition
- Prior art date
Links
- 229940125763 bromodomain inhibitor Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- UWZAJPITKGWMFJ-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Chemical compound Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O UWZAJPITKGWMFJ-UHFFFAOYSA-N 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 | |
| PCT/US2016/029029 WO2016172618A1 (en) | 2015-04-22 | 2016-04-22 | Bromodomain inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201792317A1 true EA201792317A1 (ru) | 2018-03-30 |
Family
ID=57143581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792317A EA201792317A1 (ru) | 2015-04-22 | 2016-04-22 | Ингибитор бромодомена |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (enExample) |
| EP (1) | EP3285770A4 (enExample) |
| JP (1) | JP2018513863A (enExample) |
| KR (1) | KR20170139119A (enExample) |
| CN (1) | CN107613981A (enExample) |
| AR (1) | AR104340A1 (enExample) |
| AU (1) | AU2016252992A1 (enExample) |
| BR (1) | BR112017022691A2 (enExample) |
| CA (1) | CA2983446C (enExample) |
| CL (1) | CL2017002679A1 (enExample) |
| CO (1) | CO2017011482A2 (enExample) |
| EA (1) | EA201792317A1 (enExample) |
| EC (1) | ECSP17071545A (enExample) |
| HK (1) | HK1243948A1 (enExample) |
| IL (1) | IL255120B (enExample) |
| MX (2) | MX390077B (enExample) |
| PE (1) | PE20180036A1 (enExample) |
| PH (1) | PH12017501933A1 (enExample) |
| SG (1) | SG11201708627TA (enExample) |
| TW (1) | TW201642860A (enExample) |
| WO (1) | WO2016172618A1 (enExample) |
| ZA (1) | ZA201707186B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN110099685A (zh) * | 2016-10-20 | 2019-08-06 | 赛尔基因光迪斯研究公司 | 溴结构域抑制剂 |
| ES2907840T3 (es) | 2016-10-27 | 2022-04-26 | Celgene Quanticel Res Inc | Terapia combinada de inhibidor de proteína de bromodominio y extraterminal |
| KR20210058817A (ko) * | 2018-07-23 | 2021-05-24 | 셀젠 콴티셀 리서치, 인크. | 브로모도메인 억제제의 제조 방법 |
| US20220265618A1 (en) * | 2021-02-22 | 2022-08-25 | Celgene Quanticel Research, Inc. | Methods of treating prostate cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| RS63733B1 (sr) * | 2013-10-18 | 2022-12-30 | Celgene Quanticel Research Inc | Inhibitori bromodomena |
| CN110099685A (zh) * | 2016-10-20 | 2019-08-06 | 赛尔基因光迪斯研究公司 | 溴结构域抑制剂 |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX377159B (es) | 2025-03-07 |
| AU2016252992A1 (en) | 2017-11-09 |
| NZ736630A (en) | 2024-03-22 |
| EP3285770A1 (en) | 2018-02-28 |
| CN107613981A (zh) | 2018-01-19 |
| MX390077B (es) | 2025-03-20 |
| KR20170139119A (ko) | 2017-12-18 |
| WO2016172618A1 (en) | 2016-10-27 |
| JP2018513863A (ja) | 2018-05-31 |
| IL255120B (en) | 2021-03-25 |
| CL2017002679A1 (es) | 2018-05-25 |
| CA2983446C (en) | 2024-04-09 |
| MX2020010899A (es) | 2022-02-15 |
| BR112017022691A2 (pt) | 2018-07-17 |
| PE20180036A1 (es) | 2018-01-09 |
| US20160310423A1 (en) | 2016-10-27 |
| ECSP17071545A (es) | 2017-12-01 |
| AR104340A1 (es) | 2017-07-12 |
| EP3285770A4 (en) | 2018-10-31 |
| SG11201708627TA (en) | 2017-11-29 |
| CO2017011482A2 (es) | 2018-01-31 |
| IL255120A0 (en) | 2017-12-31 |
| CA2983446A1 (en) | 2016-10-27 |
| TW201642860A (zh) | 2016-12-16 |
| HK1243948A1 (zh) | 2018-07-27 |
| MX2017013501A (es) | 2018-02-09 |
| ZA201707186B (en) | 2019-01-30 |
| PH12017501933A1 (en) | 2018-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792317A1 (ru) | Ингибитор бромодомена | |
| EA201800367A1 (ru) | Способы лечения болезни хантингтона | |
| CR20200545A (es) | Inhibidores magl | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| MX2018000412A (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2). | |
| EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| EA201792259A1 (ru) | Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения | |
| EA201991073A1 (ru) | Ингибиторы magl | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| EA201991074A1 (ru) | Ингибиторы magl | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| NI202100018A (es) | Moduladores de la expresión de pnpla3 | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| TN2019000106A1 (en) | Novel compounds for treating parasitic disease | |
| BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
| BR112018012949A2 (pt) | reguladores cftr e métodos de uso dos mesmos | |
| BR112018009745A2 (pt) | compostos heterocíclicos para o tratamento de doença | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| BR112018012934A2 (pt) | reguladores cftr e métodos de uso dos mesmos | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| BR112022008365A2 (pt) | Inibidores de cd73 |